Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

Alyssa I. Clay-Gilmour, Shaji K Kumar, S Vincent Rajkumar, Abdul Rishi, Robert A. Kyle, Jerry A. Katzmann, David L. Murray, Aaron D. Norman, Alexandra J. Greenberg, Dirk R. Larson, Megan M. O’Byrne, Susan L Slager, Celine M Vachon

Research output: Contribution to journalArticle

Abstract

We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Neoplasms
Trisomy
Fluorescence In Situ Hybridization
Age of Onset
Cytogenetics
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. / Clay-Gilmour, Alyssa I.; Kumar, Shaji K; Rajkumar, S Vincent; Rishi, Abdul; Kyle, Robert A.; Katzmann, Jerry A.; Murray, David L.; Norman, Aaron D.; Greenberg, Alexandra J.; Larson, Dirk R.; O’Byrne, Megan M.; Slager, Susan L; Vachon, Celine M.

In: Leukemia, 01.01.2018.

Research output: Contribution to journalArticle

Clay-Gilmour, AI, Kumar, SK, Rajkumar, SV, Rishi, A, Kyle, RA, Katzmann, JA, Murray, DL, Norman, AD, Greenberg, AJ, Larson, DR, O’Byrne, MM, Slager, SL & Vachon, CM 2018, 'Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics', Leukemia. https://doi.org/10.1038/s41375-018-0246-2
Clay-Gilmour, Alyssa I. ; Kumar, Shaji K ; Rajkumar, S Vincent ; Rishi, Abdul ; Kyle, Robert A. ; Katzmann, Jerry A. ; Murray, David L. ; Norman, Aaron D. ; Greenberg, Alexandra J. ; Larson, Dirk R. ; O’Byrne, Megan M. ; Slager, Susan L ; Vachon, Celine M. / Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. In: Leukemia. 2018.
@article{f573cf35b3464cc1a3c9eac75c7e06e3,
title = "Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics",
abstract = "We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8{\%} (95{\%} CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95{\%} CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.",
author = "Clay-Gilmour, {Alyssa I.} and Kumar, {Shaji K} and Rajkumar, {S Vincent} and Abdul Rishi and Kyle, {Robert A.} and Katzmann, {Jerry A.} and Murray, {David L.} and Norman, {Aaron D.} and Greenberg, {Alexandra J.} and Larson, {Dirk R.} and O’Byrne, {Megan M.} and Slager, {Susan L} and Vachon, {Celine M}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41375-018-0246-2",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

AU - Clay-Gilmour, Alyssa I.

AU - Kumar, Shaji K

AU - Rajkumar, S Vincent

AU - Rishi, Abdul

AU - Kyle, Robert A.

AU - Katzmann, Jerry A.

AU - Murray, David L.

AU - Norman, Aaron D.

AU - Greenberg, Alexandra J.

AU - Larson, Dirk R.

AU - O’Byrne, Megan M.

AU - Slager, Susan L

AU - Vachon, Celine M

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.

AB - We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=85053561924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053561924&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0246-2

DO - 10.1038/s41375-018-0246-2

M3 - Article

C2 - 30201985

AN - SCOPUS:85053561924

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -